Kush M. Parmar
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Kush M. Parmar
Kush M. Parmar was last confirmed as Board Member at Entrada Therapeutics, Inc. (TRDA) in a filing dated April 25, 2025. Earlier roles on record: Board Member at Rallybio Corp (RLYB) until October 31, 2024 and Board Member at Q32 Bio Inc. (QTTB) until September 6, 2022. Rallybio Corp reported in an 8-K filed September 17, 2024 that Kush M. Parmar resigned as member of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board, effective October 31, 2024. Q32 Bio Inc. reported in an 8-K filed September 8, 2022 that Kush M. Parmar resigned as member of the Board, effective September 6, 2022. Q32 Bio Inc. reported in an 8-K filed September 8, 2022 that Kush M. Parmar resigned as Chairman of the Board, effective September 6, 2022.
“On September 16, 2024, Dr. Kush Parmar informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he intends to resign as a member of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board effective October 31, 2024.”
“replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2018-01-01–2024-10-31
-
2018-01-01–2024-10-31
-
2016-01-01–2025-04-25
Last confirmed by a filing; no departure on record
-
2015-01-01–2022-09-06
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.